Tenaya Therapeutics (TNYA) Net Cash Flow (2020 - 2026)

Tenaya Therapeutics has reported Net Cash Flow for 7 years, with the latest figure at -$19.7 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 139.76% year-over-year to -$19.7 million; the trailing twelve-month figure through Mar 2026 stood at $27.1 million (up 567.98% YoY), and the FY2025 full-year result was $96.2 million, up 331.19% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$19.7 million, down from $44.2 million in the prior quarter.
• The five-year high for Net Cash Flow was $60.8 million in Q4 2022, with the low at -$49.9 million in Q3 2024.
• Average Net Cash Flow over 5 years is $2.5 million, with a median of $3.0 million recorded in 2023.
• Year-over-year, Net Cash Flow plunged 12587.63% in 2022 and jumped 1231.91% in 2025.
• Tracing TNYA's Net Cash Flow over 5 years: stood at $60.8 million in 2022, then slumped by 160.01% to -$36.5 million in 2023, then soared by 89.28% to -$3.9 million in 2024, then jumped by 1231.91% to $44.2 million in 2025, then tumbled by 144.44% to -$19.7 million in 2026.
• The last three Net Cash Flow figures came in at -$19.7 million (Q1 2026), $44.2 million (Q4 2025), and -$6.4 million (Q3 2025), per Business Quant data.

Peer Comparison